QUEST DIAGNOSTICS INC (DGX) Form 10-Q — Jul 23, 2026

$DGXForm 10-QFiled Jul 23, 2026, 4:16 PM ET0001022079-26-000070Original filing

Quest Diagnostics reported net revenues of $3.04 billion for the second quarter of 2026, an increase of 10.2% compared to the prior year period, driven principally by organic revenue growth of 10.0%. Net income attributable to Quest Diagnostics increased 13.4% to $320 million, while diluted earnings per share rose 15.0% to $2.84. The company completed a transaction with Corewell Health in January 2026, forming a new entity to perform laboratory testing in Michigan, which contributed to organic volume growth. Management highlighted its Invigorate program, which aims to deliver 3% annual cost savings to offset inflationary pressures.

Key figures

Eps: 2.84
Revenue: 3043
Net Income: 320
Total Debt: 5632
Cash Position: 626
Eps growth 3m percent: 15
Revenue growth 3m percent: 10.2
Revenue growth 6m percent: 9.7
Shares repurchased 6m millions: 100

Price after filing

1 day: +1.4%7 days: +13.3%30 days: +18.2%

Close on the filing date to close N calendar days later (from $206.84). Historical, not a forecast.

AI analysis

Red flags3 · Pro

The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.

Upgrade to Pro · $49/mo billed annually

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.